Patients whose tumor showed a strong pTyr-RTK signal, pTyr-EGFR for example, would likely respond to the corresponding inhibitor, e.g. Necitumumab, a WT EGFR inhibitor [5]. This evidence concerns the gene EGFR and neoplasm.